The atrial fibrillation (AF) with increasing annual incidence has become one of the most common arrhythmia in clinical practice, with cerebral embolism being its major complication. Although anticoagulant therapy is still the principal means of prevention of cerebral apoplexy, both warfarin and other new anticoagulant drugs have some limitations and are often contraindicated or underutilized. Given that the left atrial appendage (LAA) has proved as the main position of thrombogenesis in patients with AF, percutaneous LAA closure is becoming a new choice of replacing warfarin in AF patients to reduce the risk of stroke.